Penumbra系统在真实世界急性缺血性卒中血管内治疗中的COMPLETE注册研究结果
术后mTICI 2b-3达87.8%,90天mRS 0-2为55.8%,全因死亡率15.5%,与既往严格筛选的随机试验结果相当。
要点
- 真实世界中Penumbra系统一线取栓术后mTICI 2b-3再通率达87.8%。
- 90天良好功能结局(mRS 0-2)为55.8%,全因死亡率15.5%。
- 真实世界血管造影、临床与安全结局与既往随机试验相当。
核心结论
- 真实世界中使用Penumbra系统作为大血管闭塞急性缺血性卒中一线机械取栓治疗,其血管造影、临床和安全结局与既往严格站点和术者筛选的随机临床试验相当。
研究设计与样本
- 患者接受Penumbra系统联合或不联合3D Revascularization Device作为一线机械取栓治疗。
主要发现
- 术后mTICI 2b-3再通率为87.8%(95%CI 85.3%-90.4%)。
- 首次通过和术后mTICI 2c-3率分别为41.5%和66.2%。
- 90天mRS 0-2率为55.8%(95%CI 51.9%-59.7%),90天全因死亡率为15.5%(95%CI 12.8%-18.3%)。
关键数值与推荐
- 主要疗效终点为术后血管造影再通(mTICI≥2b)和90天功能结局(mRS 0-2)。
- 主要安全终点为90天全因死亡率。
- 影像核心实验室判定mTICI评分、ASPECTS、血栓位置及24小时颅内出血;独立医学评审裁定安全终点。
临床怎么用
- Penumbra系统作为一线取栓策略在真实世界大血管闭塞急性缺血性卒中患者中可获得与随机试验相当的再通和功能结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: The purpose of the COMPLETE (International Acute Ischemic Stroke Registry With the Penumbra System Aspiration Including the 3D Revascularization Device) registry was to evaluate the generalizability of the safety and efficacy of the Penumbra System (Penumbra, Inc, Alameda) in a real-world setting. METHODS: COMPLETE was a global, prospective, postmarket, multicenter registry. Patients with large vessel occlusion-acute ischemic stroke who underwent mechanical thrombectomy using the Penumbra System with or without the 3D Revascularization Device as frontline approach were enrolled at 42 centers (29 United States, 13 Europe) from July 2018 to October 2019. Primary efficacy end points were successful postprocedure angiographic revascularization (modified Thrombolysis in Cerebral Infarction ≥2b) and 90-day functional outcome (modified Rankin Scale score 0-2). The primary safety end point was 90-day all-cause mortality. An imaging core lab determined modified Thrombolysis in Cerebral Infarction scores, Alberta Stroke Program Early CT Scores, clot location, and occurrence of intracranial hemorrhage at 24 hours. Independent medical reviewers adjudicated safety end points. RESULTS: Six hundred fifty patients were enrolled (median age 70 years, 54.0% female, 49.2% given intravenous recombinant tissue-type plasminogen activator before thrombectomy). Rate of modified Thrombolysis in Cerebral Infarction 2b to 3 postprocedure was 87.8% (95% CI, 85.3%-90.4%). First pass and postprocedure rates of modified Thrombolysis in Cerebral Infarction 2c to 3 were 41.5% and 66.2%, respectively. At 90 days, 55.8% (95% CI, 51.9%-59.7%) had modified Rankin Scale score 0 to 2, and all-cause mortality was 15.5% (95% CI, 12.8%-18.3%). CONCLUSIONS: Using Penumbra System for frontline mechanical thrombectomy treatment of patients with large vessel occlusion-acute ischemic stroke in a real-world setting was associated with angiographic, clinical, and safety outcomes that were comparable to prior randomized clinical trials with stringent site and operator selection criteria. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03464565.
引用
- Zaidat OO, Fifi JT, Nanda A, et al. Endovascular Treatment of Acute Ischemic Stroke With the Penumbra System in Routine Practice: COMPLETE Registry Results. Stroke. 2021. PMID: 34547927. doi:10.1161/STROKEAHA.121.034268
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。